MegaGen Implant "11 Consecutive Years as Europe's No.1 Exporter... Breaking All-Time Record"

Megagen Implant (CEO Park Kwang-beom, hereinafter referred to as Megagen) announced on the 29th that it has set a new record for the longest consecutive export period in the dental industry by achieving the number one position in European exports for 11 consecutive years.

Celebrating its 22nd anniversary this year, Megagen is a leading Korean implant and dental medical device specialized company exporting implants and medical devices to about 100 countries. Following its 11 consecutive years as the top exporter to Europe, Megagen also holds the record for being the number one exporter to the United States for three consecutive years. Based on clinically proven technology for over 21 years, Megagen provides comprehensive dental implant solutions such as AnyRidge, Blue Diamond Implant, and ARi®.

As a frontrunner in digital technology, a major topic in the dental industry, Megagen has developed programs such as ‘R2 GATE,’ which analyzes and predicts the patient’s dental condition to enable implant surgery in a more accurate and safe position, and ‘R2 STUDIO Q,’ which goes beyond simple CT scans by creating a Digital Patient (virtual patient) in just 5 minutes to establish error-free diagnosis and appropriate treatment plans for actual patients. These innovations are leading the popularization of digital dentistry, a method that digitizes patients’ oral information to apply optimized treatment.

Despite uncertain external economic conditions such as geopolitical risks, Megagen’s solid position in the global market is the result of bold investments focusing on product and business advancement, including ▲innovative technology and R&D capabilities as core growth drivers ▲maintaining global market leadership and education/marketing activities ▲expanding production capacity through facility expansion and stabilizing logistics, thereby strengthening its number one market share position.

The foundation of Megagen’s strong product competitiveness and longest consecutive export record lies in patented technologies such as the ‘XPEED surface treatment technology,’ which deposits calcium on the implant fixture surface, and the ‘KnifeThread design,’ featuring sharp blade-shaped threads that shorten the osseointegration period by securing high initial fixation strength, thereby reducing healing time.

Recognizing these patented technologies, Megagen became the first in the implant industry to receive the ‘IR52 Jang Young-sil Award’ twice, an award hosted by the Ministry of Science and ICT that honors companies with excellent new technologies, originality, and technological innovation achievements, thereby acknowledging its technological prowess and innovation.

Furthermore, following 2022, Megagen proactively obtained the CE MDR international certification, which strengthens quality system and product performance and safety requirements under the European Medical Device Regulation, twice last year?the first in the domestic dental implant sector. It has also won the ‘Clean Implant Award,’ a global implant reliability certification award, for seven consecutive years, continuously proving its reliability and safety, which are key factors in implant selection, and maintaining recognition for global-level quality capabilities.

Additionally, through operating the global clinical education institution MINEC, Megagen provides an optimal clinical education system for dental clinicians worldwide. Based on educational activities in various countries, it regularly holds international symposiums to create a platform for the advancement of dentistry, showcasing the solutions developed by Megagen to date, and opening a space for sharing to provide better treatment to patients.

Megagen is also recognized for its continuous efforts to advance dentistry by hosting MEGA’MIND, an event aimed at discovering and nurturing future leaders in implant education who will play active roles on the global stage, thereby solidifying brand trust and awareness and achieving significant results.

To actively respond to increasing global demand, Megagen expanded its second factory on a 11,893㎡ site near its headquarters in the Seongseo 5th Industrial Complex, establishing a focused production system by item and rapidly expanding market share in the unit chair market. This bold investment and business advancement strategy has maintained market dominance and achieved both qualitative and quantitative growth by improving production efficiency.

A Megagen official stated, “Even amid diversification of export markets, we have been able to maintain the number one global market share and elevate the status of K-Implants by presenting differentiated products based on core technology, which is the key to export competitiveness. This year as well, we will continue to contribute to strengthening national industrial competitiveness and increasing exports based on stable performance growth and world-class technological competitiveness.”